Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 9/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.40 |
| ▸ | ATR | Q13535 | 6/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 5/20 | 0.37 |
| ▸ | PDCD1 | Q15116 | 5/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 5/20 | 0.37 |
| ▸ | ATRIP | Q8WXE1 | 4/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2912224 | 1.00 | PIK3CA (0.40) | PIK3CAPIK3CDATRACACBCHEK1 | |
| SCHEMBL3066827 | 1.00 | PIK3CA (0.40) | PIK3CAPIK3CDATRACACBCHEK1 | |
| SCHEMBL3059640 | 0.88 | AURKA (0.36) | PIK3CAPIK3CDATRMTORPIK3R1 | |
| SCHEMBL3059638 | 0.88 | AURKA (0.36) | PIK3CAPIK3CDATRMTORPIK3R1 | |
| SCHEMBL2910573 | 0.84 | KDM4E (0.41) | PIK3CAPIK3CD | |
| SCHEMBL2910571 | 0.84 | KDM4E (0.41) | PIK3CAPIK3CD | |
| SCHEMBL2913101 | 0.84 | KDM4E (0.41) | PIK3CAPIK3CD | |
| SCHEMBL2904249 | 0.74 | ATR (0.44) | PIK3CAPIK3CDATRCHEK1PDCD1 | |
| Hydrochloric Acid SCHEMBL2907606 | 0.73 | ATR (0.43) | PIK3CAPIK3CDATRCHEK1PDCD1 | |
| Hydrochloric Acid SCHEMBL2909842 | 0.73 | ATR (0.43) | PIK3CAPIK3CDATRCHEK1PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2789338-A2 | Condensed pyridine derivate and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2014-10-15 | — | — | EP | disclosed |
| US-20100266504-A1 | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-21 | — | — | US | disclosed |
| EP-2216023-A1 | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100266504-A1 | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF | HTR2C, HTR5A, HTR3C | PIK3CA 3931/4885PIK3CD 2931/4885ATR 3661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.